tbuckley/cabot-search huggingface dataset:
Predictors of survival in patients undergoing post-chemotherapy retroperitoneal lymph node dissection
Authors: P. E. Spiess, G. A. Brown, P. Liu, N. M. Tannir, S. Tu, A. M. Kamat, L. L. Pisters
Journal: Journal of Clinical Oncology (2006)

4593 Background: The majority of patients with testicular cancer have a favorable prognosis yet a subset of patients will succumb to this disease. The aim of this study was to identify the clinical and pathological parameters which predict the outcome of patients post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND). Methods: From 1980 to 2003, 236 patients with clinical stage IIA-III non-seminoma germ cell tumors (NSGCT) underwent a PC-RPLND. We retrospectively reviewed their medical records for pertinent clinical and treatment-related outcomes. The 5-year disease-specific and recurrence-free survival was 85% and 75%, respectively with the median length of follow-up following RPLND of 45 months (6 to 250 months). Results: The median age of patients at diagnosis was 28 years with all patients receiving systemic chemotherapy (median of 5 cycles) prior to RPLND. On multivariate analysis, predictors of disease-specific survival (DSS) included systemic symptoms at presentation (P = 0.05), elevated pre-RPLND serum alpha fetoprotein (AFP, P = 0.006) and ß-human chorionic gonadotropin (HCG, P = 0.004), post-operative complications (P = 0.03), and recurrence (P &lt; 0.0001). Predictors of recurrence-free survival (RFS) included advanced clinical stage (IIC-III, P = 0.001) and presence of viable tumor in the RPLND specimen (P = 0.03). A pre-RPLND serum AFP &gt; 9 ng/ml and HCG &gt; 4.1 mIU/ml was found to predict DSS (P = 0.03 and 0.03, respectively). Conclusions: Survival of patients undergoing PC-RPLND can be predicted by pre-operative tumor markers, and by development of post-operative complications or recurrence. Advanced clinical stage and viable tumor in the surgical specimen predict RFS. No significant financial relationships to disclose.
COMPARISON OF LONG-TERM OUTCOMES WITH BIODEGRADABLE POLYMER DRUG ELUTING STENTS AND DURABLE POLYMER DRUG ELUTING STENTS: AN UPDATED META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Authors: Byomesh Tripathi, Michael Kost, Moses Ashukem, Katheryne Marchbanks, David Biglari, Rajkumar Sugumaran, Ligita Centorino, Nickalaus Gramze, Ali Mehr, Francisco Arabia, Wilber Su, Anantharam Kalya, Arshad Banday, Firas Abbas, Samuel Butman, Nachiket Patel, Peter Weiss, Robert Hurst, Samuel Unzek Freiman, Martha Gulati, Radha Gopalan, Divya Ratan Verma
Journal: Journal of the American College of Cardiology (2020)
Patterns of presentation and management of non-small cell lung cancer in an Algerian cancer center.
Authors: Houda Jamous, Taha Filali
Journal: Journal of Clinical Oncology (2013)

e19063 Background: To evaluate the pattern of management and outcome of patients with NSCLC in our cancer center over the last 8 years. Methods: A retrospective study of all NSCLC patients seen between January 2005 and December 2012 in Medical Oncology Center, Constantine, Algeria. All demographic, clinical data, management and outcome were captured and analyzed. Results: 581 patients with NSCLC, male-female ratio 10:4, median age 59.7 years (21-85), 64.2% were smokers (0.8% were females), and 15% exposed to alcohol. Diagnostic specimens were obtained by CT scanguided biopsy in 62% of cases, bronchoscopy in 26.2%, and surgical biopsy in 9.6%. Median time to diagnosis was 6.1 months (0 months -6 years). During the study period, incidence of squamous cell carcinoma declined from 62.1% to 37.5% and adenocarcinoma incidence doubled(from 29.5% to 57.5%). Most of the patients had an advanced stage disease, 58.5% stage IV, 15.3% stage IIIB, 14.5% stage IIIA, stageIIB 4.1%, stage IIA 0.9%, stage IB 1.9%, and stage IA 0.9%. 8.6% underwent surgery, 13.9% received radiotherapy, 88.6% with PS≤ 2 received first-line chemotherapy which was platinum-based in 95.1% of the cases. 17.2% second-line, and 3.6% third-line. Most used chemotherapy regimens are: etoposide-cisplatin (EP) in 2005-2006, cisplatin-gemcitabine (P/GMZ) 2007-2009, taxotere-cisplatin (TP) 2010-2012. Outcome of these regimens ranged for response rate (RR) between 12.8% and 23.8% and overall disease control (ODC) ranged between 17.8% and 30.5%. Pemetrexed/platinum administered to 20 patients, RR 10.5%, ODC 26.1%. Bevacizumab/carboplatin-paclitaxel to 8 patients, RR 12.5%, ODC 25%. Outcomes in nonsmokers are better compared to smoker patients: RR 16.6% vs 12.1%. ODC 22.5% vs 18.2%. Longer survival (2.3 months more) and higher survival rate noted for women than that for men at all stages of the disease. RR is 16.3% in adenocarcinoma cases, 12.5% in squamous cell. For all groups: One year survival 16.5%, 2 years 5.5%, and 5 years 1%. Conclusions: Patients with NSCLC present with advanced stages. The management of NSCLC at our Center mirrored the evolution of management using conventional chemotherapy.
Preoperative letrozole plus lapatinib/placebo for HR+/HER2 negative operable breast cancer: Biomarker analyses of the randomized phase II LET-LOB study.
Authors: Valentina Guarneri, Antonio Frassoldati, Daniele Giulio Generali, Alberto Bottini, Katia Cagossi, Giancarlo Bisagni, Corrado Boni, Luigi Cavanna, Federico Piacentini, Stefania Raffaella Bettelli, Guido Ficarra, Antonino Maiorana, Luca Marini, Pier Franco Conte
Journal: Journal of Clinical Oncology (2013)

530 Background: This is a randomized, double-blind, placebo controlled study aimed to evaluate the clinical and biological effects of letrozole + lapatinib or placebo as neoadjuvant therapy in previously untreated hormone receptor positive/HER2 negative operable breast cancer. Methods: 92 postmenopausal patients with stage II-IIIA breast cancer were randomly assigned to 6 months letrozole-lapatinib (Arm A, n=43) or letrozole-placebo (Arm B, n= 49). Clinical response was evaluated according to RECIST. The following biomarkers were centrally evaluated by IHC on diagnostic core biopsy and on surgical specimens: HER2, Ki-67, EGFR, pAKT, PTEN. PIK3CA mutations were evaluated by pyrosequencing. Results: 81 patients were evaluable by USG, 8 were assessed with mammography and/or palpation. Three patients who discontinued therapy and withdrew consent were counted as non-responders according to the ITT analysis. No differences in terms of objective response rate (partial+complete response) were observed between the two arms (70% vs 63%). The percentage of patients achieving disease progression, disease stabilization, partial response and complete response were 2%, 23%, 58%, 12% respectively in the letrozole-lapatinib arm, and 6%, 29%, 61%, 2% respectively in the letrozole-placebo arm. No patients achieved pCR. All the patients were centrally confirmed as having HER2 negative disease. A significant decrease in Ki67 and pAKT expression from baseline to surgery was observed in both arms. A trend for a greater Ki67 suppression was observed in responding patients (mean Ki67 suppression -8.8 in responders vs -3.6 in non responders, p= 0.06). A mutation in PIK3CA exon 9 or 20 was observed in 37% of the patients. Overall, no differences in response were observed according to PIK3CA mutations, however, in the letrozole-lapatinib arm, the probability of achieving a clinical response was significantly higher in the PIK3CA mutation subgroup (ORR 93% vs 63% in PIK3CA WT, Pearson’s chi2 p=0.040). Conclusions: This is the first trial showing a significant correlation between PIK3CA mutation and response to letrozole-lapatinib in Hormone Receptor +/HER2- disease. Clinical trial information: NCT00422903.
DIFFERENTIAL DIAGNOSIS OF PATIENTS PRESENTING WITH ISOLATED OF MID-VENTRICULAR WALL MOTION ABNORMALITIES AND NORMAL CORONARY ANGIOGRAMS
Authors: Lukas Salazar, Sebastian Gallo, Azucena Martinez, JULIAN GELVES, Julian F. Forero, Claudia Jaimes, Hector Medina
Journal: Journal of the American College of Cardiology (2020)
Pulmonary blastoma: A clinical study of three cases.
Authors: Jose D Sandoval-Sus, Damien Mikael Hansra, Roberto Enrique Ochoa, Mario Ponce, Edgardo S. Santos
Journal: Journal of Clinical Oncology (2012)

e18109 Background: Pulmonary blastoma (PB) is a rare biphasic neoplasm composed of both immature mesenchymal and epithelial cells representing 0.2-0.5% of pulmonary malignancies. Initial presentation ranges from asymptomatic to classical symptoms of advanced pulmonary tumors. Surgical resection is the preferred treatment with no consensus on the role of other adjuvant therapies. Methods: We report the clinical features of PB in 3 patients (pts). Retrospective review of medical records of pts diagnosed with pulmonary blastoma at Jackson Memorial Hospital, Miami, FL since 2009. Staging was done using the 2009 AJCC staging system for NSCLC. All cases required to have confirmed pathological diagnosis before inclusion. Variables analyzed were demographics, clinical presentation, treatments and outcomes. Results: Mean age at diagnosis was 53 years old; two were male; 2 were Hispanic and one African American. Two of them were heavy smokers (80 and 45 packs year, respectively). At diagnosis, all cases where symptomatic; one had mild hypercalcemia of 12.9 mg/dL and two where stage IV with confirmed metastatic disease (bone and thyroid gland). Two of the cases where treated with surgical resection and both achieved complete remission (CR); one pt still remains on CR after 8 months post-surgery and the other one relapsed after 22 months post-surgery. This pt was placed on palliative chemotherapy (3 cycles of cisplatin/docetaxel) with no response. Further palliation was radiotherapy (37 Gy) with no response. The other case was treated with chemotherapy alone (6 cycles of cisplatin/docetaxel) and attained partial remission. All 3 patients remain alive. Conclusions: In our case series, all pts were symptomatic at diagnosis and two presented with metastatic disease. Surgery was the most beneficial intervention in regard to CR and disease-free interval as in previous reports. Chemotherapy has shown mixed responses, thus, larger studies are needed to define the role of chemotherapy in the adjuvant and palliative settings.
PERSISTENT GENDER AND RACIAL DIFFERENCES IN MORTALITY FROM ISCHEMIC HEART DISEASE AND CEREBROVASCULAR DISEASE IN THE UNITED STATES: 1999 TO 2017
Authors: Mohammed Essa, Augustin Delago, Matthew Hammond-Haley, Joseph Shalhouub, Dominic Marshall, Justin Salciccioli, Lissa Sugeng
Journal: Journal of the American College of Cardiology (2020)
<i>Notes from the Field:</i> Opioid-Involved Overdose Deaths with Fentanyl or Fentanyl Analogs Detected — 28 States and the District of Columbia, July 2016–December 2018
Authors: Julie O’Donnell, R. Matt Gladden, Bruce A. Goldberger, Christine L. Mattson, Mbabazi Kariisa
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

The declines in overdose deaths with fentanyl analogs (carfentanil, furanylfentanyl, acrylfentanyl, and cyclopropylfentanyl) detected contributed to declines in opioid-involved overdose deaths during 2018 among a subset of states, even as deaths with fentanyl detected increased over time, which highlights the continued need to test for fentanyl analogs.
CLO20-058: Characteristics of Gynecological Anamnesis and its Prognostic Role in Azerbaijani Women With Breast Cancer
Authors: Sevinj E. Rahimzade, Jamil A. Aliyev, Elkhan E. Kazimov, Leylakhanum A. Melikova, Konul S. Mardanova, Turkan E. Mansurova, Elchin B. Mansurov
Journal: Journal of the National Comprehensive Cancer Network (2020)
A SYSTEMIC REVIEW AND META-ANALYSIS OF VALVE IN VALVE TRANSCATHETER AORTIC VALVE REPLACEMENT COMPARING BALLOON AND SELF EXPANDING VALVES
Authors: Garry Hamilton, Anoop Koshy, Alexandra Murphy, Jordan Fulcher, James Theuerle, Omar Farouque, Mark Horrigan, Matias Yudi
Journal: Journal of the American College of Cardiology (2020)
A matched pair analysis of conditioning BuEM versus BEAM in autologous haematopoietic cell transplantation for lymphomas in terms of toxicity and efficacy.
Authors: Ioanna Sakellari, Despina Mallouri, Ioannis Batsis, Chryssoula Apostolou, Varnavas Konstantinou, Elma Maria Abela, Vassiliki Douka, Anastasia Marvaki, Kyriakos Karypidis, Iskas Michail, Panayiotis Baliakas, Panayiotis Kaloyannidis, Evangelia Yannaki, George Kouvatseas, Christos Smias, Achilles Anagnostopoulos
Journal: Journal of Clinical Oncology (2013)

8567 Background: In autologous hematopoietic cell transplantation (AHCT) for lymphomas, the optimal conditioning regimen is currently investigated. The standard conditioning used is BEAM. During 2009-2011 a new alternative Busulphan-based conditioning regimen constructed in our unit, consisting of Busilvex (9.6 mg/Kg), Etoposide (9.6 mg/Kg) and Melphalan (140mg/m^2) (BuEM) was used. We retrospectively analysed the outcome of patients (pts) conditioned with BEAM and BuEM regimen, in terms of toxicity and efficacy, in a matched pair analysis. Methods: A matched paired analysis on a 1:2 ratio was performed. Thus, 2 control cases (receiving BEAM regimen) were matched to each patient treated with BuEM according to: phase of transplant, age, lines of previous chemotherapy. The first 50 consecutive pts treated with BuEM were matched to a random sample from the historical BEAM control population. Ninety-three BEAM pts that fulfilled the matching criteria were eventually randomly selected. Concerning pts characteristics there were no statistical significant differences except from more chemoresistant disease in the BuEM cohort (p=0.008). Thus a second matched pair analysis was conducted upon stratification by disease chemosensitivity instead of age as a risk factor. Results: Progression free survival and overall survival (OS) were 70.6% and 81.8% for the BEAM vs 68.9% and 83% for the BuEM cohort respectively (p=ns). In the BuEM cohort a borderline significantly better OS was noted in Hodgkin’s pts receiving BuEM (p=0.05). In terms of early toxicity a significantly faster neutrophil engraftment was found in the BEAM cohort, but there was a significantly less need of red blood cells, platelet transfusions and GCSF infusion in the BuEM cohort. BEAM regimen was also associated with: reduced incidence of infections (p=0.02), less severe (grade 3-4) mucositis (p=0.000) and liver toxicity (p=0.004). Conclusions: BEAM regimen was correlated with a favourable reduced early toxicity profile, ie severe mucositis and liver impairment. On the other hand, BuEM was found to be equally efficacious and moreover offered improved overall survival in Hodgkin’s lymphoma pts.
OBSTRUCTIVE SLEEP APNEA PREDICTS RECURRENCE OF ATRIAL ARRHYTHMIAS FOLLOWING CRYOBALLOON ABLATION IN PATIENTS WITH PAROXYSMAL ATRIAL FIBRILLATION
Authors: Abhishek Bose, Parag Anilkumar Chevli, Zeba Hashmath, Ajay K. Mishra, Gregory Berberian, Ghasan Ahmad, Jerzy Januszkiewicz, Hafiz Ghafoor, Douglas Laidlaw
Journal: Journal of the American College of Cardiology (2020)
VERY LONG-TERM COMPLICATIONS IN 132 PATIENTS WITH TRANSPOSITION OF THE GREAT ARTERIES WHO RECEIVED THE ATRIAL SWITCH OPERATION
Authors: Darren Harrison, Chris Broda, Peter Ermis, Angeline Opina, Dhaval Parekh, Wayne J. Franklin, Jeffrey Kim, Athar Quereshi, Wilson Lam
Journal: Journal of the American College of Cardiology (2020)
IMPACT OF HIGH-DENSITY LIPOPROTEIN ON THE OVERALL SURVIVAL IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
Authors: Manpreet Kaur, Keerat Rai Ahuja, Anas Saad, Mohamed M. Gad, Chandramohan Meenakshisundaram, Kamalpreet Dhaliwal, Shameer Khubber, Beni Rai Verma, Johnny Chahine, Parth Parikh, Toshiaki Isogai, Andrew J. Toth, Rishi Puri, Leslie Cho, Stephen Ellis, Russell E. Raymond, Ravi Nair, Samir R. Kapadia
Journal: Journal of the American College of Cardiology (2020)
BPA and risk assessment
Authors: Antonia M Calafat, Holger M Koch, SS Andra, JP Antignac, A Castaño, K Choi, A Covaci, W Dekant, DR Doerge, H Frederiksen, T Göen, M Kolossa-Gehring, A Leblanc, JF Mueller, SF Nakayama, J Nassif, A St-Amand, W Völkel, MS Wolff
Journal: The Lancet Diabetes & Endocrinology (2020)
CLINICAL CHARACTERISTICS AND MORPHOLOGICAL CULPRIT PLAQUE FEATURES IN PATIENTS WITH ACUTE CORONARY SYNDROME
Authors: Akira Nagasawa, Hiromasa Otake, Hiroyuki Kawamori, Takayoshi Toba, Hiroyuki Onishi, Yoichiro Sugizaki, Ryo Takeshige, Shinsuke Nakano, Yoichiro Matsuoka, Kosuke Tanimura, Yu Takahashi, Yusuke Fukuyama, Shunsuke Kakizaki, Daichi Fujimoto, Koichi Nakamura, Amane Kozuki, Junya Shite, Masamichi Iwasaki, Koji Kuroda, Tomofumi Takaya, Ken-Ichi Hirata
Journal: Journal of the American College of Cardiology (2020)
Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound
Authors: Evan M. Cale, Hongjun Bai, Meera Bose, Michael A. Messina, Donn J. Colby, Eric Sanders-Buell, Bethany Dearlove, Yifan Li, Emily Engeman, Daniel Silas, Anne Marie O’Sullivan, Brendan Mann, Suteeraporn Pinyakorn, Jintana Intasan, Khunthalee Benjapornpong, Carlo Sacdalan, Eugène Kroon, Nittaya Phanuphak, Robert Gramzinski, Sandhya Vasan, Merlin L. Robb, Nelson L. Michael, Rebecca M. Lynch, Robert T. Bailer, Amélie Pagliuzza, Nicolas Chomont, Amarendra Pegu, Nicole A. Doria-Rose, Lydie Trautmann, Trevor A. Crowell, John R. Mascola, Jintanat Ananworanich, Sodsai Tovanabutra, Morgane Rolland
Journal: Journal of Clinical Investigation (2020)

Infusion of the broadly neutralizing antibody VRC01 has been evaluated in individuals chronically infected with HIV-1. Here, we studied how VRC01 infusions affected viral rebound after cessation of antiretroviral therapy (ART) in 18 acutely treated and durably suppressed individuals. Viral rebound occurred in all individuals, yet VRC01 infusions modestly delayed rebound and participants who showed a faster decay of VRC01 in serum rebounded more rapidly. Participants with strains most sensitive to VRC01 or with VRC01 epitope motifs similar to known VRC01-susceptible strains rebounded later. Upon rebound, HIV-1 sequences were indistinguishable from those sampled at diagnosis. Across the cohort, participant-derived Env showed different sensitivity to VRC01 neutralization (including 2 resistant viruses), yet neutralization sensitivity was similar at diagnosis and after rebound, indicating the lack of selection for VRC01 resistance during treatment interruption. Our results showed that viremia rebounded despite the absence of HIV-1 adaptation to VRC01 and an average VRC01 trough of 221 μg/mL. Although VRC01 levels were insufficient to prevent a resurgent infection, knowledge that they did not mediate Env mutations in acute-like viruses is relevant for antibody-based strategies in acute infection.
CLO20-057: A Meta-Analysis on Gastrointestinal (GI) and Hepatic Toxicities Associated With Upfront Use of Immune Checkpoint Inhibitor and Anti-Angiogenic Tyrosine Kinase Inhibitor Combinations for Advanced Renal Cell Carcinoma
Authors: Miguel Angel Quirch, Nusrat Jahan, Meda Srikala, Fred Hardwicke, Lukman Tijani
Journal: Journal of the National Comprehensive Cancer Network (2020)

"CLO20-057: A Meta-Analysis on Gastrointestinal (GI) and Hepatic Toxicities Associated With Upfront Use of Immune Checkpoint Inhibitor and Anti-Angiogenic Tyrosine Kinase Inhibitor Combinations for Advanced Renal Cell Carcinoma" published on 20 Mar 2020 by National Comprehensive Cancer Network.
POOR WEIGHT RECOVERY BETWEEN STAGE 1 PALLIATION AND HOSPITAL DISCHARGE: AN ANALYSIS OF THE NPC-QIC PHASE II DATASET
Authors: Rohin Moza, Dongngan Truong, Linda Lambert, Zhining Ou, Venugopal Amula, Aaron Eckhauser, L. LuAnn Minich, Richard Williams
Journal: Journal of the American College of Cardiology (2020)
Working Together to Advance Cardio-Oncology in China
Authors: Yunlong Xia, MD, PhD, Jiwei Liu, MD, PhD
Journal: JACC CardioOncology (2020)

![Figure][1] 



![Figure][1] 

The number of cancer patients and survivors is increasing in China. However, many cancer therapies have short- and long-term cardiovascular (CV) toxicities. The risk of cardiovascular disease (CVD) in cancer patients is substantially higher than the
GENETIC POLYMORPHISMS AND CARDIOVASCULAR OUTCOMES IN CHINESE PATIENTS UNDERGOING PCI AND TREATED WITH CLOPIDOGREL AND ASPIRIN
Authors: Ke Xu, Tiantian Zhu, Deyu Kong, Hui Zhu, Jimin Li, Fei Wang, Lu Yang, Yuansheng Fan, Jing Zhang, Yi Lu, Lei Xu, Mingwen Yang, Qian Gu, Lu Shi, Xiaoxuan Gong, Noel C. Chan, Chunjian Li
Journal: Journal of the American College of Cardiology (2020)
ASSOCIATION BETWEEN ORBITAL OR ROTATIONAL ATHERECTOMY AND CLINICAL OUTCOMES AMONG PATIENTS WITH CALCIFIC CORONARY ARTERY DISEASE: INSIGHTS FROM THE CLINICAL ASSESSMENT, REPORTING AND TRACKING (CART) PROGRAM
Authors: Keisuke Yasumura, Benjamin Benhuri, Artiom Petrov, Yuliya Vengrenyuk, Nitin Barman, Joseph Sweeny, Vishal Kapur, Javed Suleman, Usman Baber, Roxana Mehran, Gregg Stone, Annapoorna Subhash Kini, Samin K. Sharma
Journal: Journal of the American College of Cardiology (2020)
Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020
Authors: Angela Rose, Esther Kissling, Hanne-Dorthe Emborg, Amparo Larrauri, Jim McMenamin, Francisco Pozo, Ramona Trebbien, Clara Mazagatos, Heather Whitaker, Marta Valenciano
Journal: Eurosurveillance (2020)

Background Influenza A(H1N1)pdm09, A(H3N2) and B viruses were co-circulating in Europe between September 2019 and January 2020. Aim To provide interim 2019/20 influenza vaccine effectiveness (VE) estimates from six European studies, covering 10 countries and both primary care and hospital settings. Methods All studies used the test-negative design, although there were some differences in other study characteristics, e.g. patient selection, data sources, case definitions and included age groups. Overall and influenza (sub)type-specific VE was estimated for each study using logistic regression adjusted for potential confounders. Results There were 31,537 patients recruited across the six studies, of which 5,300 (17%) were cases with 5,310 infections. Most of these (4,466; 84%) were influenza A. The VE point estimates for all ages were 29% to 61% against any influenza in the primary care setting and 35% to 60% in hospitalised older adults (aged 65 years and over). The VE point estimates against A(H1N1)pdm09 (all ages, both settings) was 48% to 75%, and against A(H3N2) ranged from −58% to 57% (primary care) and −16% to 60% (hospital). Against influenza B, VE for all ages was 62% to 83% (primary care only). Conclusions Influenza vaccination is of continued benefit during the ongoing 2019/20 influenza season. Robust end-of-season VE estimates and genetic virus characterisation results may help understand the variability in influenza (sub)type-specific results across studies.
AI-based prognostic imaging biomarkers for precision neuro-oncology: the ReSPOND consortium
Authors: Christos Davatzikos, Jill S Barnholtz-Sloan, Spyridon Bakas, Rivka Colen, Abhishek Mahajan, Carmen Balaña Quintero, Jaume Capellades Font, Josep Puig, Rajan Jain, Andrew E Sloan, Chaitra Badve, Daniel S Marcus, Yoon Seong Choi, Seung-Koo Lee, Jong Hee Chang, Laila M Poisson, Brent Griffith, Adam P Dicker, Adam E Flanders, Thomas C Booth, Saima Rathore, Hamed Akbari, Chiharu Sako, Michel Bilello, Gaurav Shukla, Anahita Fathi Kazerooni, Steven Brem, Robert Lustig, Suyash Mohan, Stephen Bagley, MacLean Nasrallah, Donald M O’Rourke
Journal: Neuro-Oncology (2020)
THE ASSOCIATION OF CARDIOVASCULAR RISK FACTORS AND CALCIUM VOLUME, DENSITY, NUMBER, AND TYPE OF CORONARY VESSEL WITH CALCIFIED PLAQUE IN SOUTH ASIANS LIVING IN THE US AND OTHER RACIAL/ETHNIC GROUPS: COMPARING MASALA AND MESA STUDIES
Authors: Mahmoud Al Rifai, Alka Kanaya, Namratha R. Kandula, Miguel Cainzos-Achirica, Jaideep Patel, Matthew J. Budoff, Michael H. Criqui, Michael Blaha, Salim Virani
Journal: Journal of the American College of Cardiology (2020)
“SCRATCHLESS FEVER:” ACUTE SEVERE AORTIC INSUFFICIENCY SECONDARY TO INFECTIVE ENDOCARDITIS FROM BARTONELLA HENSELAE
Authors: Olubadewa A. Fatunde, Khashayar Vahdat, Shahab Akvan, Anita Scribner, Prashanth Peddi, Tiffany Egbe
Journal: Journal of the American College of Cardiology (2020)